Convalescent Plasma Use in the United States was inversely correlated with COVID-19 Mortality:

Did Plasma Hesitancy cost lives?

Arturo Casadevall MD, PhD[1*]; Quigly Dragotakes PhD[1]; Patrick W. Johnson BS[2], Jonathon W. Senefeld PhD[3], Steven A. Klassen PhD[3], R. Scott Wright MD[4], Michael J Joyner MD[3#], Nigel Paneth MD[5#]; Rickey E. Carter PhD[2#]

[1]Department of Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, Baltimore, MD; [2] Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL; [3]Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN; [4]Department of Cardiology, Mayo Clinic, Rochester, MN; [5]Department of Epidemiology and Biostatistics and Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, East Lansing, MI.

*Address Correspondence: Arturo Casadevall, 615 N. Wolfe Street, Room E5132, Baltimore, Maryland 21205, acasade1@jhu.edu

[#]MJJ, NP and REC share last authorship.

Abstract

Background. The US Food and Drug Administration authorized Convalescent Plasma (CCP) therapy for hospitalized COVID-19 patients via the Expanded Access Program (EAP) and the Emergency Use Authorization (EUA), leading to use in about 500,000 patients during the first year of the pandemic for the US.

Methods. We tracked the number of CCP units dispensed to hospitals by blood banking organizations and correlated that usage with hospital admission and mortality data.

Results. CCP usage per admission peaked in Fall 2020, with more than 40% of inpatients estimated to have received CCP between late September and early November 2020. However, after randomized controlled trials failed to show a reduction in mortality, CCP usage per admission declined steadily to a nadir of less than 10% in March 2021. We found a strong inverse correlation (r = -0.52, P = 0.002) between CCP usage per hospital admission and deaths occurring two weeks after admission, and this finding was robust to examination of deaths taking place one, two or three weeks after admission. Changes in the number of hospital admissions, SARS-CoV-2 variants, and age of patients could not explain these findings. The retreat from CCP usage might have resulted in as many as 29,000 excess deaths from mid-November 2020 to February 2021.

Conclusions. A strong inverse correlation between CCP use and mortality per admission in the USA provides population level evidence consistent with the notion that CCP reduces mortality in COVID-19 and suggests that the recent decline in usage could have resulted in excess deaths.

Introduction

In the Spring of 2020, the United States embarked on a historic and unprecedented deployment of plasma derived from patients who survived COVID-19 (COVID-19 Convalescent Plasma (CCP)) for treatment of the disease, and one-year into this effort more than 500,000 individuals have been treated. The synergism created by the lack of effective alternate therapies, a plentiful supply of plasma from an efficient and high-capacity blood banking network, motivated donors and strong community partners fueled this deployment. Sensible US FDA regulatory oversight was provided first by its Expanded Access Program (EAP) in partnership with the Mayo Clinic, with first transfusion on early April 2020,[1] and then by its Emergency Use Authorization (EUA) of August 23, 2020, both of which restricted CCP use to hospitalized patients [2].

The demonstration by the summer of 2020 that CCP was safe [3,4], that antibody in plasma correlated with survival in people treated before ventilation [5] along with initial suggestions of efficacy [6-8], fueled interest in and use of this product. However, the interpretation of the potential efficacy of CCP is complex as many of the positive findings arose through post hoc examinations and subgroup comparisons. Nonetheless, the use of CCP rose rapidly without the ideal evidence base of efficacy from randomized controlled clinical trials (RCT), since early RCTs though generally trending positively, were unsatisfactory, mostly due to small size or premature termination as the epidemic abated in the early surge regions [9]. Later in the pandemic several larger RCTs reported no mortality benefit [10-12], raising doubts as to CCP efficacy. However, these latter trials were undertaken in hospitalized patients treated late in the course of disease and some used plasma with variable antibody levels [9], and contrasted with a highly successful trial in elderly patients treated within 3 days of illness onset prior to hospitalization [13]. Despite potential explanations for the negative studies, the results of these studies were sometimes accompanied by editorials that reinforced message of futility with the British Medical Journal calling CCP 'ineffective' [14], Nature Biotechnology reported that CCP fell 'flat' [15] and JAMA published a meta-analysis of RCT concluding that there was no evidence of benefit from CCP therapy [16]. On February 17, 2021 the *Wall Street Journal* reported that Mount Sinai Hospital, which had been a leader in deploying CCP and reported early encouraging results [8], had stopped using plasma in patients with COVID-19, and the report specifically mentioned the negative results from CCP RCTs in this decision [17].

On March 13, 2021 the New York Times reported that COVID-19 mortality remained high with nearly 1,500 daily deaths despite a drop in the number of new infections since earlier in the year [18]. This finding was surprising in light of an apparent reduction in the mortality of hospitalized patients as the epidemic progressed, thought to be from improved management of the disease as clinical experience grew [19]. Analyzing weekly reports from the blood banking industry, we noted that plasma use was on the decline, based on the ratio of units dispensed to hospital admissions. The increase in mortality combined with the reduction in CCP use led us to hypothesize first, that the two phenomena were related, and second, that the decline in CCP use reflected reduced use following the disappointing trial findings. The blood banking network maintains careful and complete records for every blood product unit used including time, date and geographic provenance and destination, providing a virtually complete record of trends in CCP use for the US. We therefore examined the use of CCP units as a function of time, assessing the relationship of CCP use to COVID-19 mortality, denominating both plasma units and deaths to hospital admissions. The aim of the study was to determine whether the reduction in plasma use was associated with any change in the pattern of mortality seen in patients hospitalized for COVID-19.

Materials and Methods

Convalescent Plasma Usage. CCP usage was inferred from the distribution of plasma units to hospitals in the USA from data obtained from Blood Centers of America (BCA, West Warwick, RI). Data fields included collections, distributions to hospitals, distributions to research or other use. This file consolidated all the reports from regional blood bank reports and provided a total of collected units and units distributed to hospitals. The data file did not have information on whether a unit was actually transfused but BCA can infer usage from hospital re-ordering information and there has been a strong correlation between the total number of units shipped to a hospital and the units transfused by that hospital. Hence, the CCP units dispensed to hospitals represent a reasonable proxy value for the total number of units being transfused to patients. To validate this assumption, we compared the numbers of plasma units dispensed to those used by the EAP. There was a powerful and significant correlation between the weekly counts of units distributed in the United States and those used to treat patients as part of the EAP between April 06 and August 23, 2020. (Spearman rho = 0.953, P<0.001) (Figure S1). Units transfused in the EAP were reported by providers as part of the official case report forms and each transfusion could comprise one or two units.

Admission and mortality data. For population level data on COVID-19 admissions and mortality we relied on publicly available databases. Specifically, we used information from the Our World in Data (OWID) (https://ourworldindata.org/coronavirus) database. Data used for this analysis were downloaded on March 18, 2021 and are available as Supplemental Table S1. We confirmed these findings using Centers for Disease Control (CDC, Atlanta, GA) data on admissions and deaths https://covid.cdc.gov/covid-data-tracker/#new-hospital-admissions and https://covid.cdc.gov/covid-data-tracker/#trends_dailytrendsdeaths. CDC data were downloaded on 3/31/2021, and are available as Supplemental Table S2.

Statistical analysis. Preliminary descriptive analyses were used to explore the associations of the ratio of number of CCP units dispersed to the number of hospitalizations (CCP utilization ratio) with the ratio of national deaths to national admissions, the latter being a reasonable proxy for the case fatality rate. No individual-level data were available to link the mortality events directly to the individuals hospitalized to permit a calculation of the true case-fatality rate. To address this limitation, the mortality counts reported by the CDC were shifted to better align the deaths with the admitted patients. Since the overwhelming majority of COVID-19 deaths occur in hospitals [20,21], since CCP is only authorized for use in hospitals, and since death generally occurs a few days to weeks after admission, mortality was adjusted for the time lag between admission and death. The median time between admission and death has been reported as 9 days in the US [22] and 6.7 days in Belgium [23]. For the analysis, which was based on weekly aggregated data, a two-week shift was selected to align the mortality with the median and upper quartile estimates in these reports. The Pearson correlation coefficient was used to describe the relationship of the CCP utilization ratio with CFR. To further define this relationship, a linear statistical model was used to regress the utilization ratio onto CFR. This statistical model was weighted by the number of hospitalizations per week. The fit of the model was examined using standard residual-based diagnostic plots and the fit was deemed acceptable using only a linear fit of the CCP utilization ratio.

Three in silico scenarios were created to summarize the effect of alterations to the CCP utilization ratio using the fitted model. In scenario 1, the effect of maintenance of plasma usage was considered. To define maintenance of use, a weighted average of the utilization ratio over the months of August

through September 2020 was estimated. This value was then used to estimate the number of deaths that would be expected to occur throughout the study period (admissions starting 8/3/2020 – 2/22/2021). In scenario 2 a constant 50% CCP utilization ratio was set over the entire study period. The utilization rate was approximately the value observed in the early October 2020 period. A final scenario estimated the CFR that may have been observed had CCP not been used at all (i.e., the y-intercept from the model). Model contrasts were used to estimate the change in expected deaths among these scenarios in addition to a fourth condition – the actual number of events reported by the CDC. Values are summarized based on the observed number of hospitalized patients over the study period along with the same values indexed into expected mortality events per 1000 hospitalizations. Pointwise confidence bands for each scenario were obtained by multiplying the model-predicted CFR, and its associated 95% confidence interval, by the number of hospitalizations per week. Cumulative summations were used to describe the differences in expected deaths over the entire study period. This analysis was repeated independently a third time using a weighted average of utilization ratio of the months October-November on a separate database (OWID) to investigate stability between reporting bodies. As a final method for estimating the overall effect of the changes in CCP utilization, the CDC data were grouped into two time periods representing relative use. The difference in the CFR was used to estimate the expected value for the changes in the expected number of deaths.

Statistical analyses were conducted using R version 3.6.2.[24] 95% confidence intervals and two-sided p-values were used to summarize association and test for significance at the alpha=0.05 level of significance, respectively.

Results

Convalescent plasma use.

The FDA first allowed compassionate use of CCP on a case-by-case basis in late March 2020, but very quickly initiated the Expanded Access Program in early April 2020. The EAP was, in effect, a registry of all CCP use in the US from April to August 2020 and led to a sharp rise in CCP use. The findings of the EAP, which established that CCP was as relatively safe [3,4], and that high antibody titer was associated with lower mortality in unventilated plasma recipients [5], were major considerations behind the Emergency Use Authorization of August 23, 2020, which broadened its use. Distribution of CCP to hospitals rose to 25,000 - 30,000 weekly units by the December 2020 to January 2021 time period, but this rise in plasma distribution largely reflected the great increase in hospital admissions for COVID in those months. (Figure 1). When CCP distributions are analyzed as a function of the number of new hospital admissions per week, peak utilization per capita occurred much earlier, in early October 2020 and declined sharply in the following months (Figure 2).

Correlation between CCP and mortality.

To explore whether there was a relationship between CCP distribution in the USA and mortality we first compared the doses per patient versus reported COVID-19 deaths per hospital admission from publicly available databases (Figure 2). The comparison of curves showed a trough in deaths per admission coinciding with the peak of CCP usage per admission. A plot of mortality versus doses per hospitalized patient using mortality per admission data from the OWID database revealed a strong negative correlation (Pearson's correlation coefficient of -0.52 with P = 0.002) (Figure 3). To account for lags in the reporting of death that vary by state, we also investigated whether this correlation was maintained

while adding weeks to the time between admission and death (Figure S2). Additionally, as we show in Supplemental Figure 3, if plasma use is divided into quintiles from lowest using weeks to highest using weeks, a dose-response relationship between use of plasma and mortality is apparent.

Estimates of excess deaths.

The linear model using the CCP utilization ratio to predict the CFR fit the data well in that this model explained 25% (R^2 = 0.254) of the variance of CFR using only the CCP utilization ratio. The model estimated the CFR decreased by 1.8 percentage points for every 10-percentage point increase in the rate of utilization of CCP (p = 0.004). The linear regression analysis yielded a mortality in patients not receiving CCP of 25.2% as the y-intercept. A comparison of this number with that from USA studies shows reasonable agreement between with the average mortality of 23.5% in patients not receiving CCP (Table S3). This percentage also closely matches the 24% mortality for COVID-19 patients for the large RECOVERY trial in the United Kingdom [12] and the 30% mortality of patients receiving late CCP in analysis from the Expanded Access Program [5]. An extrapolation of the linear model to the situation where every patient is treated with CCP yields a mortality of 7.6%, which is lower than the average mortality in USA studies, but still within the range reported (Table S3). However, this extrapolation to maximal use is much less reliable given the absence of points in the y axis region above an CCP utilization ratio of 0.6 and uncertainty as to whether the relationship is linear in those ranges. Hence, we caution the reader about making any strong inference from this estimate while noting that it is close to the 6.2% mortality reported for COVID-19 patients treated with high titer CCP very early upon hospitalization [25]. Nevertheless, it is possible to use these efficacy numbers to estimate what the effect on deaths would have been had the United States continued to use CCP at the height of its usage in early Fall 2020, when more than 40% of all patients received plasma therapy.

With this model as a framework for estimating the excess number of deaths, the results of three scenarios were obtained (Figure 4). The total observed deaths over the study period was 356,534. Had the rate of CCP utilization observed during August through October 2002 carried over for the remaining months, the expected number of deaths was 327,516 (95%: CI: 293,811 to 361,221), which would result in 29,018 (95% CI: 3535 to 54,501) fewer deaths than observed. This excess death, in comparison, was small relative to the estimate that results from assuming plasma utilization was as high as it was after the EUA was issued. Had 50% utilization of plasma been continued, 62,383 (95% CI: 7599 to 117,166) fewer deaths may have been observed. Under the most extreme scenario comparing no plasma use to the highest observed use, a difference of 158,409 (95% CI: 19,296 to 297,523) deaths is estimated. We repeated this analysis independently for each of the databases used (CDC vs OWID) with concordant results (Figure S5 and Tables S1, S2).

As an alternative method to estimating the excess deaths, which alleviated the need for a model, the data were summarized into two key periods (Table 1). In each of the seven weeks from September 21st to November 8th, 2020, the estimated proportion of in-patients transfused with convalescent plasma 42.6%. The two-week lagged mortality ratio for hospitalized patients was 18.16%. In the following period from 11/9/2021 to the week starting 3/22/21, transfusion rates declined steadily, averaging 27.4%. In parallel, mortality ratio rose to 20.08% for the 1,344,463 patients admitted in those 18 weeks. Table 1 shows that if the mortality rate in those 18 weeks had been the same as during the high-transfusion period, 25,871 fewer deaths would have taken place.

Discussion

The use of CCP in hospitalized patients peaked from mid-September to the end of October 2020 shortly after the FDA allowed its widespread use under the EUA of August 23, 2020. This increase was not blunted by some claims that evidence of efficacy was insufficient for the authorization, [26,27] However, RCTs from India [10] and Argentina [11] reporting that CCP use did not reduce mortality in hospitalized patients were followed by a decline in use in November. This decline was accelerated after the RECOVERY trial in the UK issued a January, 2021 news release announcing no effect of CP on mortality [12]. The pattern suggests that physicians were more influenced by clinical research data than by the controversies that played out in the media. A poll by the American Association of Blood Banks revealed a 50% increase in the number of institutions planning to stop offering CCP between February and March 2021, which cited lack of stronger efficacy data as the major reason for this decision [28].

The results show that CCP use per hospital admission closely paralleled the severity of the epidemic throughout much of 2020, increasing in parallel with hospital admissions, but then declined late in 2020 and in the early months of 2021, a time following the publication of several negative RCT studies. Of concern, the drop in per capita CCP utilization appeared to be associated with an increase in mortality among hospitalized COVID-19 patients. If there is a causal link between these two trends, we estimate that the decline in per capita CCP use resulted in 29,000-36,000 excess deaths. Given that this analysis was done during the ongoing pandemic and that the variables that affect mortality are not fully understood we urge caution with our findings. Nevertheless, applying Occam's razor to the problem, the results do raise the disturbing possibility that reduced CCP use may have contributed to the deaths of thousands of patients.

While the relationship we describe needs to be interpreted with caution, several aspects of the evidentiary landscape point to CPP efficacy when used appropriately.

- An analysis of several dozen studies for which results were available by mid-January 2021 associated the administration of CCP with reduced mortality, with an effect size of ~35% [29].
- Convalescent plasma has proven effective in individuals with defective humoral immunity and B cell defects [30,31].
- The active agent in plasma, antibody titer, is strongly related to mortality in transfused patients [5,13,32]
- The active agent of CCP, specific antibody to SARS-CoV-2, has powerful antiviral activity and has been shown to reduce the viral load in patients with COVID-19, thus providing a mechanistic explanation for its therapeutic effect [33].
- Human convalescent plasma is protective in murine models of COVID-19 [34].
- Patients treated with CCP manifest reduced inflammatory markers [35-37] that can lead to host damage. [38]
- Research has identified nine places where plasma affects the cascade of inflammation to the benefit of treated patients [39].

Late use of plasma, or use in people with advanced illness, is not likely to be effective, because at that time, the inflammatory response itself is the major pathophysiologic pathway to severe illness and death, by which time antibody is powerless to change the course of illness. [40]

The results of RCTs are mixed, but many trials treated very advanced disease. For example, while the overall findings of the RECOVERY trial were null [12], patients treated early in the course of illness (before antibody conversion, in the first seven days, not receiving steroids or oxygen) all showed lower mortality in the CPP arm.

The observed association between CCP use per hospitalized patient and mortality helps define the potential for effectiveness of this therapy at a population level. This inference is strengthened by the fact that mortality from COVID-19 among hospitalized patients decreased substantially over most of 2020, consistent with worldwide trends [19], but then began to rise in late November and early December 2020, a period that coincided with precipitous reduction in CCP/admission.

Buttressing such a conclusion would require excluding the contribution of other variables that can affect mortality, which is challenging during an ongoing pandemic where information about the pathophysiology and clinical course of COVID-19 is accruing rapidly. Three factors can be excluded. The mean age of the hospital population with COVID-19 was actually older during peak use of CCP than later. The number of hospital admissions per week was not associated with increased mortality. The occasional delay seen in recording of death certificate information would apply largely to the most recent months when mortality was already highest. This analysis – based as it is on ecological correlations - must acknowledge some critical limitations. Many possible confounders are not available to evaluate for this analysis.

The emergence of SARS-CoV-2 variants with higher mortality is another variable that must be considered. In the United Kingdom a new lineage of SARS-CoV-2 emerged in the September 2020 known as B.1.1.7, which is associated with higher contagiousness and perhaps, mortality [41]. This variant was identified in the United States in early winter 2021 but as of January only 76 cases had been described in 12 states, which was estimated to be <0.5% of the infections at the time [42]. Hence this variant constituted a small minority of cases during much of the time involved in our analysis. Even as late as mid-March 2021 the CDC estimated that B.1.1.17 variant comprised only 25% of US isolates and increased mortality from these infections would not manifest itself until times later than our analysis [43]. Limiting our analysis to the time from March 2020 to January 2021 shows maintenance of the trends described here.

Taking a page from the reluctance of citizens to accept vaccines against SARS-CoV-2, a phenomenon that has been termed 'vaccine hesitancy' [44], we call the phenomenon of reduced use of CCP 'plasma hesitancy'. In this regard, we note that both the vaccines being administered in the USA and CCP are being used under a EUA regulatory framework, since neither has full approval status and that these hesitancies lead to avoidance behaviors based on the interpretation of available data by the public and health care providers, respectively. Plasma hesitancy may be a result of health care providers overvaluing and over-emphasizing negative results from RCT findings while dismissing other evidence that CCP reduces mortality. On the other hand, remdesevir has been widely embraced by the health care provider community for treatment of Sars-CoV2, despite a lack published data on reductions in mortality from its use and with conflicting RCT data regarding its clinical usefulness [45,46]. In contrast, CCP has some data demonstrating a reduction in mortality for hospitalized patients with COVID-19 from its early use in non-ventilated patients[29], and clear evidence of effectiveness in outpatients[13] and yet has met with use hesitancy.

Why might this be? One possibility is that there is relatively little recent experience with treating infectious diseases with antibody therapies [40]. The different receptions for plasma and for chemical agents could reflect confirmational bias by a health care community experienced in the successful use of antiviral drugs against Human immunodeficiency (HIV) and Hepatitis C (HCV) viruses.

In summary, CCP is one of few options available to physicians for treating COVID-19. It is available wherever there are recovered patients, it is relatively inexpensive and has a good safety profile [3]. With regards to its efficacy, we have argued that physicians need to consider all the evidence, from observational studies to RCTs, when evaluating clinical efficacy data [47]. We note that the FDA reaffirmed the EUA status of CCP in February 2021 [2] by permitting its continued use in hospitalized patients if used early in COVID-19 and with units that have a sufficient content of specific antibody. In addition, interim guidelines for American Association of Blood Banks [48] and Brazil [49] emphasize that CCP is more likely to be effective when used in early COVID-19 with units having high content of specific antibody. We are hopeful that physicians consider the totality of the available evidence, including our findings, when making decisions for CCP use in individual patients.

Acknowledgements

We are grateful to Bill Block and Jennifer Kapral from Blood Centers of America, Inc. (West Warwick, RI) and Kate Fry from America Blood Centers (Washington, DC) for their help in obtaining the plasma usage data. AC was supported in part by RO1 HL059842 and R01 AI152078 9; MJJ was supported in part by 5R35HL139854. This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority under Contract No. 75A50120C00096.

Disclaimer: The views and opinions expressed in this publication are those of the authors and do not reflect the official policy or position of the US Department of Health and Human services and its agencies including the Biomedical Research and Development Authority and the Food and Drug Administration, as well as any agency of the U.S. government. Assumptions made within and interpretations from the analysis are not reflective of the position of any U.S. government entity.

References

1.   Senefeld JW, Johnson PW, Kunze KL, et al. Program and patient characteristics for the United States Expanded Access Program to COVID-19 convalescent plasma. medRxiv 2021:2021.04.08.21255115.
2.   Anonymous. Investigational COVID-19 Convalescent Plasma. Guidance for Industry. In: Administration FaD, ed.2021.
3.   Joyner MJ, Wright RS, Fairweather D, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. The Journal of clinical investigation 2020;130:4791-7.
4.   Joyner MJ, Bruno KA, Klassen SA, et al. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clinic proceedings 2020;95:1888-97.
5.   Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. New England Journal of Medicine 2021.
6.   Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA 2020;324:460-70.
7.   Salazar E, Christensen PA, Graviss EA, et al. Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality. The American journal of pathology 2020;190:2290-303.
8.   Liu STH, Lin HM, Baine I, et al. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nature medicine 2020;26:1708-13.
9.   Casadevall A, Grossman BJ, Henderson JP, et al. The Assessment of Convalescent Plasma Efficacy against COVID-19. Med (New York, NY) 2020;1:66-77.
10.   Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). Bmj 2020;371:m3939.
11.   Simonovich VA, Burgos Pratx LD, Scibona P, et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. The New England journal of medicine 2021;384:619-29.
12.   Horby PW, Estcourt L, Peto L, et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv 2021:2021.03.09.21252736.
13.   Libster R, Perez Marc G, Wappner D, et al. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. The New England journal of medicine 2021;384:610-8.
14.   Pathak EB. Convalescent plasma is ineffective for covid-19. Bmj 2020;371:m4072.
15.   Sheridan C. Convalescent plasma falls flat in first randomized trial. Nat Biotechnol 2020.
16.   Janiaud P, Axfors C, Schmitt AM, et al. Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. Jama 2021;325:1185-95.
17.   Marcus A. New York's Mount Sinai Ends Blood-Plasma Treatment for Hospitalized Covid-19 Patients. Wall Street Journal 2021 February 21, 2021.
18.   Leatherby L. Despite Encouraging Downward Trend, U.S. Covid Deaths Remain High. New York Times 2021 March 13, 2021.
19.   Ledford H. Why do COVID death rates seem to be falling? Nature 2020;587:190-2.
20.   Chua IS, Shi SM, Levine DM. Place of Death and End-of-Life Care Utilization among COVID-19 Decedents in a Massachusetts Health Care System. Journal of palliative medicine 2021;24:322-3.
21.   Chuzi S, Molsberry R, McCabe ME, et al. Distribution in Place of Death for COVID-19-Related Mortality in the United States. Journal of the American Geriatrics Society 2020;68:1917-8.

22.   Horwitz LI, Jones SA, Cerfolio RJ, et al. Trends in COVID-19 Risk-Adjusted Mortality Rates. Journal of hospital medicine 2021;16:90-2.
23.   Faes C, Abrams S, Van Beckhoven D, Meyfroidt G, Vlieghe E, Hens N. Time between Symptom Onset, Hospitalisation and Recovery or Death: Statistical Analysis of Belgian COVID-19 Patients. International journal of environmental research and public health 2020;17.
24.   Team RC. R: A language and environment for statistical computing. 2013.
25.   Salazar E, Christensen PA, Graviss EA, et al. Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG. The American journal of pathology 2021;191:90-107.
26.   Pau AK, Aberg J, Baker J, et al. Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel. Ann Intern Med 2021;174:93-5.
27.   Baden LR, Solomon CG, Greene MF, D'Agostino RB, Harrington D. The FDA and the Importance of Trust. The New England journal of medicine 2020;383:e148.
28.   Anonymous. AABB Survey: CCP usage reevaluation March 2021. American Association of Blood Banks; 2021.
29.   Klassen SA, Senefeld JW, Johnson PW, et al. The Effect of Convalescent Plasma Therapy on COVID-19 Patient Mortality: Systematic Review and Meta-analysis. Mayo Clinic proceedings; 2021: Elsevier.
30.   Thompson MA, Henderson JP, Shah PK, et al. Convalescent Plasma and Improved Survival in Patients with Hematologic Malignancies and COVID-19. medRxiv 2021:2021.02.05.21250953.
31.   Senefeld JW, Klassen SA, Ford SK, et al. Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency. medRxiv 2020:2020.11.08.20224790.
32.   Maor Y, Cohen D, Paran N, et al. Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma. EClinicalMedicine 2020;26:100525.
33.   Kim MS, An MH, Kim WJ, Hwang TH. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. PLoS medicine 2020;17:e1003501.
34.   Sun J, Zhuang Z, Zheng J, et al. Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment. Cell 2020;182:734-43.e5.
35.   Bandopadhyay P, Rozario R, Lahiri A, et al. Nature and dimensions of the systemic hyper-inflammation and its attenuation by convalescent plasma in severe COVID-19. The Journal of infectious diseases 2021.
36.   Tremblay D, Seah C, Schneider T, et al. Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients. Cancer medicine 2020.
37.   Wu J, Shen J, Han Y, et al. Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment. Frontiers in immunology 2021;12:598799.
38.   Pirofski LC, A. Pathogenesis of COVID-19 from the perspective of the damage-response framework. mbio 2020;11:e01175-20.
39.   Acosta-Ampudia Y, Monsalve DM, Rojas M, et al. COVID-19 convalescent plasma composition and immunological effects in severe patients. Journal of autoimmunity 2021;118:102598.
40.   Casadevall A, Pirofski LA, Joyner MJ. The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19. mBio 2021;12.
41.   Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. Bmj 2021;372:n579.

42.   Galloway SE, Paul P, MacCannell DR, et al. Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-January 12, 2021. MMWR Morbidity and mortality weekly report 2021;70:95-9.

43.   Variant Proportions in the United States. 2021. at https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-proportions.html.)

44.   Pullan S, Dey M. Vaccine hesitancy and anti-vaccination in the time of COVID-19: A Google Trends analysis. Vaccine 2021;39:1877-81.

45.   Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. The New England journal of medicine 2020;383:1813-26.

46.   Dyer O. Covid-19: Remdesivir has little or no impact on survival, WHO trial shows. Bmj 2020;371:m4057.

47.   Casadevall A, Joyner M, Paneth N. A Victory or Scientific Pragmatism. The New Atlantis2021.

48.   Cohn CS, Estcourt L, Grossman BJ, et al. COVID-19 convalescent plasma: Interim recommendations from the AABB. Transfusion 2021;61:1313-23.

49.   De Santis GC, Mendrone A, Langhi D, Jr., et al. Suggested guidelines for convalescent plasma therapy for the treatment of COVID-19. Hematology, transfusion and cell therapy 2021.

50.   Shenoy AG, Hettinger AZ, Fernandez SJ, Blumenthal J, Baez V. Early mortality benefit with COVID-19 convalescent plasma: a matched control study. British journal of haematology 2021.

51.   Donato ML, Park S, Baker M, et al. Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma. JCI insight 2021;6.

52.   Yoon HA, Bartash R, Gendlina I, et al. Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC. JCI insight 2021;6.

53.   O'Donnell MR, Grinsztejn B, Cummings MJ, et al. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. medRxiv 2021:2021.03.12.21253373.

54.   Sostin OV, Rajapakse P, Cruser B, Wakefield D, Cruser D, Petrini J. A matched cohort study of convalescent plasma therapy for COVID-19. Journal of clinical apheresis 2021.

55.   Sturek JM, Thomas TA, Gorham JD, et al. Convalescent plasma for preventing critical illness in COVID-19: A phase 2 trial and immune profile. medRxiv 2021.

Table 1. Estimated number of excess deaths due to transfusion hesitancy.

Time Period	Transfusion Rate	Number of Admissions	Deaths	Mortality Rate	Expected deaths if mortality had remained at 18.16%	Excess deaths in the low transfusion period	Excess deaths per 1000 admissions
High Utilization (9/21/2020 - 11/8/2020)	42.59%	257,424	46,747	18.16%	46,747	--	--
Low Utilization (11/9/2021 - 3/22/21)	27.43%	1,344,463	270,019	20.08%	244,148	25,871	19.2

Table S1. Data from and calculations for excess mortality from CCP hesitancy based on the OWID database.

Week	Plasma Doses	Deaths	Hospitalized Patients	Admissions	Plasma Doses Per Patient	Mortality (Deaths / Admissions - 2 Week Shift)
7/18/2020	11231	5559	38045	21481	0.52	0.37
7/25/2020	12919	6513	42802	33434	0.39	0.22
8/1/2020	11724	7855	49972	38256	0.31	0.19
8/8/2020	10511	7421	41313	33153	0.32	0.20
8/15/2020	10495	7126	38655	31543	0.33	0.20
8/22/2020	9218	6711	34466	30226	0.30	0.19
8/29/2020	8968	6309	31031	29776	0.30	0.17
9/5/2020	8424	5855	28242	27010	0.31	0.20
9/12/2020	7894	5124	26237	28351	0.28	0.19
9/19/2020	9647	5348	25382	23924	0.40	0.21
9/26/2020	11670	5439	25915	24867	0.47	0.21
10/3/2020	11101	4939	27804	27575	0.40	0.19
10/10/2020	14796	5172	31370	33658	0.44	0.17
10/17/2020	16401	5222	34934	37027	0.44	0.16
10/24/2020	17827	5812	39899	40935	0.44	0.18
10/31/2020	18628	6012	45983	46467	0.40	0.18
11/7/2020	19205	7303	55640	56877	0.34	0.20
11/14/2020	26176	8156	69432	70999	0.37	0.15
11/21/2020	28076	11119	81702	81834	0.34	0.20
11/28/2020	28688	10814	92351	86841	0.33	0.21
12/5/2020	27350	16033	98549	94573	0.29	0.20
12/12/2020	25706	17907	107227	101624	0.25	0.16
12/19/2020	29842	19238	112272	104959	0.28	0.22
12/26/2020	24350	16363	118892	106311	0.23	0.22
1/9/2021	30576	23074	126420	116363	0.26	0.19
1/16/2021	28946	23726	120658	108721	0.27	0.20
1/23/2021	25395	21843	106881	93972	0.27	0.22
1/30/2021	20226	22152	91286	80589	0.25	0.22
2/6/2021	18913	20667	77709	69080	0.27	0.19
2/13/2021	12303	17346	63237	55607	0.22	0.25
2/20/2021	8369	13155	53512	46421	0.18	0.25
2/27/2021	8429	13706	44799	41727	0.20	NA
3/6/2021	6006	11791	NA	32075	0.19	NA

Table S2. Replicate excess death calculations based on OWID database.

Week	Scenario 1		Scenario 2		Scenario 3	
Transfused	38.90%		50%		0%	
Week	Expected Deaths	Difference	Expected Deaths	Difference	Expected Deaths	Difference
8/1/2020	3974.94	3880.06	3625.35	4229.65	5332.66	1707.31
8/8/2020	6186.78	1234.22	5642.66	1778.34	8299.99	2657.33
8/15/2020	7079.06	46.94	6456.47	669.53	9497.05	3040.59
8/22/2020	6134.78	576.22	5595.23	1115.77	8230.23	2635.00
8/29/2020	5836.86	472.14	5323.51	985.49	7830.55	2507.04
9/5/2020	5593.16	261.84	5101.24	753.76	7503.60	2402.36
9/12/2020	5509.89	-385.89	5025.30	98.70	7391.89	2366.60
9/19/2020	4998.05	349.95	4558.48	789.52	6705.23	2146.75
9/26/2020	5246.20	192.80	4784.80	654.20	7038.14	2253.34
10/3/2020	4427.00	512.00	4037.65	901.35	5939.13	1901.48
10/10/2020	4601.50	570.50	4196.80	975.20	6173.23	1976.43
10/17/2020	5102.60	119.40	4653.83	568.17	6845.49	2191.66
10/24/2020	6228.23	-416.23	5680.46	131.54	8355.60	2675.14
10/31/2020	6851.64	-839.64	6249.05	-237.05	9191.95	2942.91
11/7/2020	7574.80	-271.80	6908.60	394.40	10162.11	3253.51
11/14/2020	8598.46	-442.46	7842.24	313.76	11535.43	3693.20
11/21/2020	10524.78	594.22	9599.13	1519.87	14119.72	4520.58
11/28/2020	13137.97	-2323.97	11982.50	-1168.50	17625.50	5643.00
12/5/2020	15142.93	890.07	13811.12	2221.88	20315.29	6504.17
12/12/2020	16069.45	1837.55	14656.16	3250.84	21558.28	6902.12
12/19/2020	17500.21	1737.79	15961.09	3276.91	23477.75	7516.66
12/26/2020	18804.96	-2441.96	17151.08	-788.08	25228.16	8077.08
1/9/2021	19422.09	3651.91	17713.93	5360.07	26056.07	8342.14
1/16/2021	19672.27	4053.73	17942.11	5783.89	26391.71	8449.60
1/23/2021	21532.33	310.67	19638.58	2204.42	28887.11	9248.53
1/30/2021	20118.22	2033.78	18348.84	3803.16	26989.99	8641.15
2/6/2021	17389.00	3278.00	15859.65	4807.35	23328.55	7468.89
2/13/2021	14912.55	2433.45	13601.01	3744.99	20006.22	6405.21
2/20/2021	12782.87	372.13	11658.63	1496.37	17149.11	5490.48
2/27/2021	10289.77	3416.23	9384.79	4321.21	13804.44	4419.64
3/6/2021	8589.95	3201.05	7834.47	3956.53	11524.01	3689.54
Excess Deaths		28904.69		57913.24		141669.44

Table S3. Mortality of COVID-19 in USA CCP efficacy studies.

Study	Location	Type	Mortality		Relative risk of death with plasma	Reference
			CCP	Control		
Salazar et al.	Houston, TX	Matched Cohort Design	6.2	12.5	0.50	25
Liu et al.	New York City	Matched Cohort Design	12.8	24.4	0.52	8
Shenoy et al.	Washington, DC	Matched Cohort Design	25	27	0.93	50
Donato et al.	New Jersey	Matched Cohort Design	11.1	27.1	0.41	51
Yoon et al.	New York City	Matched Cohort Design	32.8	37.5	0.87	52
O'Donnell et al.	New York City	Double Blind Randomized Controlled	12.6	24.6	0.51	53
Sostin et al.	Hartford, CT	Matched Cohort Design	20	24.6	0.81	54
Sturek et al.	Charlottesville, VA	Matched Cohort Design	6.9	10.4	0.66	55
Average			15.9	23.5	0.68	

Table S4. Data from and calculations for excess mortality from CCP hesitancy based on the CDC database.

Starting date for seven-day period for Hospitalizations	Starting date for seven-day period for deaths	Plasma Distributions	Deaths	Hospitalizations	Plasma Doses Per Patient	Mortality (Deaths / Admissions - 2 Week Shift)
2020-08-03	2020-08-17	10511	6854	31448	0.3342343	0.2179471
2020-08-10	2020-08-24	10495	6395	29914	0.3508391	0.2137795
2020-08-17	2020-08-31	9218	5894	28841	0.3196144	0.2043618
2020-08-24	2020-09-07	8968	5154	28335	0.3164990	0.1818952
2020-08-31	2020-09-14	8424	5316	25850	0.3258801	0.2056480
2020-09-07	2020-09-21	7894	5301	24432	0.3231009	0.2169695
2020-09-14	2020-09-28	9647	4854	22795	0.4232068	0.2129414
2020-09-21	2020-10-05	11670	4905	23851	0.4892877	0.2056518
2020-09-28	2020-10-12	11101	4895	26365	0.4210506	0.1856628
2020-10-05	2020-10-19	14796	5592	32198	0.4595316	0.1736754
2020-10-12	2020-10-26	16401	5775	35493	0.4620911	0.1627081
2020-10-19	2020-11-02	17827	6651	39595	0.4502336	0.1679758
2020-10-26	2020-11-09	18628	8482	45067	0.4133401	0.1882087
2020-11-02	2020-11-16	19205	10447	54855	0.3501048	0.1904475
2020-11-09	2020-11-23	26176	10158	69243	0.3780310	0.1467007

Starting date for seven-day period for Hospitalizations	Starting date for seven-day period for deaths	Plasma Distributions	Deaths	Hospitalizations	Plasma Doses Per Patient	Mortality (Deaths / Admissions - 2 Week Shift)
2020-11-16	2020-11-30	28076	15177	80036	0.3507921	0.1896272
2020-11-23	2020-12-07	28688	17031	84937	0.3377562	0.2005133
2020-11-30	2020-12-14	27350	18634	92813	0.2946785	0.2007693
2020-12-07	2020-12-21	25706	15526	99678	0.2578904	0.1557616
2020-12-14	2020-12-28	29842	18425	102606	0.2908407	0.1795704
2020-12-21	2021-01-04	24350	22605	103921	0.2343126	0.2175210
2020-12-28	2021-01-11	25475	23334	109965	0.2316646	0.2121948
2021-01-04	2021-01-18	30576	21711	114279	0.2675557	0.1899824
2021-01-11	2021-01-25	28946	21978	106434	0.2719620	0.2064942
2021-01-18	2021-02-01	25395	20351	92383	0.2748882	0.2202894
2021-01-25	2021-02-08	20226	17991	79549	0.2542584	0.2261625
2021-02-01	2021-02-15	18913	13455	67999	0.2781364	0.1978706
2021-02-08	2021-02-22	12303	13553	54321	0.2264870	0.2494984
2021-02-15	2021-03-01	8369	11938	45664	0.1832735	0.2614313
2021-02-22	2021-03-08	8429	8152	40635	0.2074320	0.2006152

Figure 1. Doses of CCP distributed in the United States by the American Red Cross and American Blood Centers (dashed) and total COVID-19 cases in the United States reported in OWID (solid). The vertical black line marks August 23, 2020 when the FDA announced that Emergency Use Authorization for CCP in the USA. The vertical gray line marks April 4, 2020 as the start of the Emergency Access Program.

Figure 2. Doses of CCP per hospital admission (red) and mortality calculated as deaths per hospital admission (green). To account for time between admission to death, deaths from two weeks after admission are used to calculate mortality. The vertical line marks August 23, 2020 when the FDA announced that Emergency Use Authorization for CCP in the USA.

Figure 3. Correlation of mortality (death per admission) and CCP doses per admitted patients. Correlation analysis yields a Pearson's correlation coefficient of -0.518 (p = 0.0024). The black line represents a linear model regression with an R squared of 0.268.

Figure 4. Estimated deaths under modeled scenarios of Covid-19 Convalescent Plasma. Panel A presents the longitudinal observed (dashed line) and modeled number of deaths under three scenarios for CCP over the study period (8/3/2020 – 2/22/2021) that included 356,534 deaths in 1,793,502 hospitalized patients. Over the entire study period, the CCP utilization ratio was 29.1%. In the scenario labeled maintenance of plasma, the CCP utilization ratio was set to 39.5%. With the no plasma and 50% plasma usage scenarios, the CCP utilization ratio was set at 0% and 50%, respectively. Panel B provides the pairwise comparisons of these scenarios to estimate the difference in expected number of deaths among the scenarios for the entire hospitalized patients (upper right triangle) and re-indexed to events per 1000 patients (lower left triangle). The rows represent the comparator or reference scenario, columns indicate the altered CCP use scenario. For example, the cell that intersects the observed deaths and the maintenance of plasma column shows that 29,018 fewer deaths would result had plasma use remained at the 39.5% level.

Supplementary Figure 1. Correlation of convalescent plasma distribution and usage within the Expanded Access Program. Shown is the progressive increase in the number of convalescent plasma units distributed in the United States and convalescent plasma units used in the Expanded Access Program (EAP). Data between April 06 and August 23, 2020 are pooled in weekly intervals and represented as filled circles. The Pearson correlation coefficient was used to assess correlation (r= 0.946, P<0.001) and a LOESS smoother with a 95% confidence interval (CI) and a reference line were overlayed. Points below the reference line represent weeks where more convalescent plasma was distributed than used within the EAP. Conversely, points above the reference line are indicative of more convalescent plasma being used in the EAP than distributed.

Supplemental Figure 2. A series of linear regressions and Pearson's correlation tests comparing weekly reported deaths to new weekly hospital admissions, offset by various numbers of weeks to identify the length of lag between admission and death of patients. Y axes values reflect the parameter of each gray box throughout the shifted weeks. Correlations peak at 2-3 weeks shifted, suggesting the lag time between admission and reported death is roughly two weeks

Supplemental Figure 3. Mortality from COVID-19 by quintile of percent of admissions receiving CCP.

Supplemental Figure 4. Investigation of high age group mortality. The shifted mortality is compared to the percent of hospitalized patients 65+ each week as reported by the CDC. There is no significant correlation between the two variables, suggesting changes in mortality are not explainable by an increase in hospitalized high risk patients.

Supplemental Figure 5. Replicated cumulative excess deaths analysis per OWID database for scenario 1 (orange) : Maintained plasma transfusion rate from Oct-Nov throughout period, scenario 2 (blue): 50% transfusion rate throughout period, and scenario 3 (red): 0% transfusion rate throughout period. Black dashed line represents observed cumulative deaths per OWID reporting.